Abstract:Despite the decline in their proliferative potential, senescent cells display a high metabolic activity. Senescent cells have been shown to acquire a more glycolytic state even in presence of high oxygen levels, in a way similar to cancer cells. The diversion of pyruvate, the final product of glycolysis, away from oxidative phosphorylation results in an altered bioenergetic state and may occur as a response to the enhanced oxidative stress caused by the accumulation of dysfunctional mitochondria. This metabolic shift leads to increased AMP/ATP and ADP/ATP ratios, to the subsequent AMPK activation, and ultimately to p53-mediated growth arrest. Mounting evidences suggest that metabolic reprogramming is critical to direct considerable amounts of energy toward specific activities related to the senescent state, including the senescence-associated secretory phenotype (SASP) and the modulation of immune responses within senescent cell tissue microenvironment. Interestingly, despite the relative abundance of oxygen in the vascular compartment, healthy endothelial cells (ECs) produce most of their ATP content from the anaerobic conversion of glucose to lactate. Their high glycolytic rate further increases during senescence. Alterations in EC metabolism have been identified in age-related diseases (ARDs) associated with a dysfunctional vasculature, including atherosclerosis, type 2 diabetes and cardiovascular diseases. In particular, higher production of reactive oxygen species deriving from a variety of enzymatic sources, including uncoupled endothelial nitric oxide synthase and the electron transport chain, causes DNA damage and activates the NAD+-consuming enzymes polyADP-ribose polymerase 1 (PARP1). These non-physiological mechanisms drive the impairment of the glycolytic flux and the diversion of glycolytic intermediates into many pathological pathways. Of note, accumulation of senescent ECs has been reported in the context of ARDs. Through their pro-oxidant, pro-inflammatory, vasoconstrictor, and prothrombotic activities, they negatively impact on vascular physiology, promoting both the onset and development of ARDs. Here, we review the current knowledge on the cellular senescence-related metabolic changes and their contribution to the mechanisms underlying the pathogenesis of ARDs, with a particular focus on ECs. Moreover, current and potential interventions aimed at modulating EC metabolism, in order to prevent or delay ARD onset, will be discussed.

Senescence of endothelial cells promotes phenotypic changes in adventitial fibroblasts: possible implications for vascular aging

High Glucose And Free Fatty Acids Induce Endothelial Progenitor Cell Senescence Via Pgc-1 Alpha/Sirt1 Signaling Pathway

Abstract 100: Omics Strategies To Identify Senescent Cells Mediating Extracellular Matrix Remodeling During Vascular Disease

MicroRNA expression with “aging” in human aortic endothelial cells

Factors and Pathways Modulating Endothelial Cell Senescence in Vascular Aging

Oxidative Glucose Metabolism Promotes Senescence in Vascular Endothelial Cells

Hypoxia-Inducible Factor-1α: The Master Regulator of Endothelial Cell Senescence in Vascular Aging

Cellular Senescence Contributes to Large Elastic Artery Stiffening and Endothelial Dysfunction With Aging: Amelioration With Senolytic Treatment

Senescence Alters PPARγ (Peroxisome Proliferator-Activated Receptor Gamma)-Dependent Fatty Acid Handling in Human Adipose Tissue Microvascular Endothelial Cells and Favors Inflammation

Cellular senescence in endothelial cells from atherosclerotic patients is accelerated by oxidative stress associated with cardiovascular risk factors

Targeting vascular senescence in cardiovascular disease with aging

Where Metabolism Meets Senescence: Focus on Endothelial Cells

Pro-ferroptotic Signaling Promotes Arterial Aging Via Vascular Smooth Muscle Cell Senescence

Angiogenic properties of aged adipose derived mesenchymal stem cells after hypoxic conditioning

Endothelial Cell Senescence Increases Traction Forces Due to Age-Associated Changes in the Glycocalyx and SIRT1

The Senescent Heart—"Age Doth Wither Its Infinite Variety"

Endothelial dysfunction and angiogenesis impairment in the ageing vasculature

Disrupted Binding of Cystathionine γ-Lyase to p53 Promotes Endothelial Senescence

Endothelial Senescence and the Chronic Vascular Diseases: Challenges and Therapeutic Opportunities in Atherosclerosis

Abstract 3138: Atheroprone Flow, Aging, And Oxysterols Impair Endothelial Cell Nuclear Health Via Disruption Of Autoregulatory Perinuclear Cytoskeletal Dynamics

Long-term stimulation of angiotensin II induced endothelial senescence and dysfunction